Swiss pharma giant
Novartis ( NVS Quick Quote NVS - Free Report) entered a global research collaboration with Artios Pharma Limited, a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer.
The companies have collaborated to discover and validate next-generation DDR targets to enhance Novartis' Radioligand Therapies (RLT).
Under the three-year collaboration, Artios and Novartis will perform target discovery and validation. Thereafter, Novartis will select up to three exclusive DDR targets and receive worldwide rights on these targets to be utilized with its RLTs.
Novartis will make an up-front payment of $20 million to Artios and provide near-term research funding to support the collaboration. Artios is also eligible to receive discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products commercialized by Novartis. The collaboration does not include Artios’ lead programs, ART0380, or ART4215, a first-in-class Pol Theta inhibitor.
Last week, Novartis expanded its radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) assets, including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc. The agreement also includes co-exclusive rights for Novartis to develop imaging applications for these assets.
Earlier, the company reported the first interpretable results from the phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to the best standard of care alone. The study met both primary endpoints of overall survival and radiographic progression-free survival.
Radioligand therapy combines a targeting compound that binds to markers expressed by tumors and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication.
Novartis is currently pursuing four different cancer treatment platforms — radioligand therapy, cell and gene therapy, targeted therapy, and immunotherapy.
Shares of Novartis have lost 7.9% so far this year compared with the
industry’s decline of 1.1%.
Novartis has a strong oncology portfolio, but competition is stiff in this space from companies like
Roche ( RHHBY Quick Quote RHHBY - Free Report) , Bristol-Myers ( BMY Quick Quote BMY - Free Report) and AstraZeneca ( AZN Quick Quote AZN - Free Report) , among others.
Novartis currently carries a Zacks Rank #3 (Hold). You can see
. the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>